MiECC vs Conventional Bypass for Heart Surgery
(MiECS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is MiECC safe compared to conventional bypass for heart surgery?
Research shows that miniaturized extracorporeal circulation (MiECC) systems, compared to conventional cardiopulmonary bypass (CPB), may reduce some complications like inflammation and blood clotting issues, but they might also have less safety margin in certain situations. Overall, both systems have been tested in many studies, and while MiECC might offer some benefits, it's important to discuss individual risks with your doctor.12345
How does MiECC differ from conventional bypass in heart surgery?
MiECC (Minimal Invasive Extracorporeal Circulation) is a more advanced and less invasive form of heart-lung machine used during heart surgery, which aims to reduce the physical stress on the body compared to conventional cardiopulmonary bypass (CPB). This approach can potentially lead to fewer complications and a quicker recovery.678910
What data supports the effectiveness of the treatment MiECC compared to conventional bypass for heart surgery?
Research suggests that minimal extracorporeal circulation (MECC) and miniaturized cardiopulmonary bypass (Mini-CPB) can be equal or better alternatives to conventional cardiopulmonary bypass (C-CPB) in terms of reducing complications and the need for blood transfusions during coronary artery bypass surgery. These treatments may be particularly beneficial for high-risk patients or complex surgeries.111121314
Who Is on the Research Team?
Kyriakos Anastasiadis, Professor
Principal Investigator
Aristotle University Of Thessaloniki
Polychronis Antonitsis, Assoc. Prof.
Principal Investigator
Aristotle University Of Thessaloniki
Are You a Good Fit for This Trial?
This trial is for patients needing elective or urgent heart surgery for coronary artery disease or aortic valve issues, using a heart-lung machine but not requiring complex aortic surgery. Participants must be able to consent and can't have blood disorders or objections to blood transfusions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo cardiac surgery using either MiECC or cCPB systems
Follow-up
Participants are monitored for postoperative complications and recovery
Extended Follow-up
Participants' health-related quality of life is assessed
What Are the Treatments Tested in This Trial?
Interventions
- Conventional cardiopulmonary bypass
- Minimal Invasive Extracorporeal Circulation
Conventional cardiopulmonary bypass is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
- Cardiac surgery
- Coronary artery bypass grafting (CABG)
- Heart transplantation
- Valve repair and replacement
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aristotle University Of Thessaloniki
Lead Sponsor
Minimal Invasive Extracorporeal Technologies International Society (MiECTiS)
Collaborator
Clinical Research Unit, School of Medicine, Aristotle University of Thessaloniki
Collaborator